Every material Form 8-K Humana filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Humana reported third-quarter 2026 financial results with GAAP earnings of $1.33 per share and an adjusted loss of $0.70 per share. The company raised its full-year 2026 adjusted EPS guidance to at least $9.50 while also expanding its CenterWell and Medicaid patient footprints.
Reported third-quarter 2026 GAAP EPS of $1.33 and an adjusted loss per share of $0.70.
Raised full-year 2026 adjusted EPS guidance to at least $9.50, up from the prior expectation of at least $9.00.
CenterWell Senior Primary Care grew by 146,800 patients year-to-date, representing a 30 percent increase.
Medicaid membership grew by 103,600 members, or 7 percent, year-to-date.
Humana's board increased its size from eleven to thirteen seats on July 28, 2026, and elected Frederick J. Crawford and Paul J. Smith as directors effective that day. The board determined both are independent under NYSE standards, and committee assignments have not yet been decided. The filing involves no financial results or guidance changes, but it adds two new directors to the board.
Board expanded from eleven to thirteen authorized directors on July 28, 2026.
Frederick J. Crawford is a former President and Chief Operating Officer of Aflac and a former CFO of several insurers.
Paul J. Smith is Chief Commercial Officer at Anthropic PBC and previously held senior roles at ServiceNow, Salesforce and Microsoft.
Both directors will receive restricted stock units under the director compensation program; no committee appointments have been made yet.
Humana reported second-quarter 2026 GAAP EPS of $5.73, up from $4.51 a year earlier, and adjusted EPS of $7.61, up from $6.27, on revenue of $40.9 billion versus $32.4 billion. The company lowered its full-year 2026 GAAP EPS guidance to at least $6.52 from at least $8.36, while affirming adjusted EPS guidance of at least $9.00, which it says reflects a year-over-year decline tied to the Star Ratings headwind.
Second-quarter 2026 GAAP EPS was $5.73 versus $4.51 in 2Q25; adjusted EPS was $7.61 versus $6.27.
Revenue was $40,867 million in 2Q26 versus $32,388 million in 2Q25; GAAP pretax results were $952 million versus $741 million.
FY 2026 GAAP EPS guidance was revised to at least $6.52 from at least $8.36; adjusted EPS guidance of at least $9.00 was affirmed.
Insurance segment GAAP benefit ratio was 91.2 percent in 2Q26, in line with management's guidance of slightly above 91 percent.
Humana completed the sale of $750 million each of Pre-Capitalized Trust Securities through two Horseshoe Funding trusts, on May 15, 2026. The structure gives Humana the right to require the trusts to buy up to $750 million each of its 6.062% Senior Notes due 2036 and 6.887% Senior Notes due 2055, and Humana pays facility fees on the unused portion.
Two trusts each sold 750,000 P-Caps for $750 million, closed May 15, 2026
Humana can issue up to $750 million of 6.062% Senior Notes due 2036 over ten years and up to $750 million of 6.887% Senior Notes due 2055 over thirty years
Facility fees accrue at 1.661% per year (2036 trust) and 1.916% per year (2055 trust) on the unexercised portion
Humana must exercise the rights in full if it reasonably believes consolidated net worth has fallen below $4.0 billion
Humana reported first-quarter 2026 revenue of $39.6 billion, up from $32.1 billion a year earlier, but GAAP earnings per share fell to $9.83 from $10.30. The company cut its full-year 2026 GAAP EPS guidance to at least $8.36 from at least $8.89 while affirming its adjusted EPS guidance of at least $9.00, so shareholders face lower reported profit expectations even as sales grew.
Q1 2026 revenue was $39.6 billion versus $32.1 billion in Q1 2025.
Q1 2026 adjusted EPS was $10.31 versus $11.58 in Q1 2025; GAAP EPS was $9.83 versus $10.30.
FY 2026 GAAP EPS guidance revised to at least $8.36 from at least $8.89; adjusted EPS guidance of at least $9.00 affirmed.
George Renaudin, Insurance Segment President, will retire effective June 29, 2026; John Barger will lead Medicare Advantage operations effective immediately.
Humana's board increased its authorized directors from ten to eleven and elected Robert S. Field as a director, effective after the April 16, 2026 annual meeting. Field is a healthcare investor who will receive restricted stock units under the company's director compensation program, and the board has determined he is independent.
Board expanded from ten to eleven authorized directors; Field's election takes effect after the April 16, 2026 annual meeting adjourns.
Field is Principal and Managing Member of ηMed Capital Management LLC, an investment firm focused on U.S. healthcare services companies.
Field will be granted restricted stock units; no committee appointments have been determined yet.
Humana sold $1.0 billion of 6.625% junior subordinated notes due September 15, 2056, at 100% of principal, and the offering closed March 9, 2026. The company expects net proceeds of about $986 million, which it intends to use for general corporate purposes, including possibly repaying debt such as commercial paper borrowings.
Principal amount of $1.0 billion; public offering price 100% of principal amount
Expected net proceeds of about $986 million after underwriting discounts and offering expenses
Fixed 6.625% rate until September 15, 2031, then resets every five years to five-year U.S. Treasury rate plus 2.891%, not below 6.625%
Company may defer interest for up to 10 consecutive years if no event of default has occurred; notes are subordinate to senior indebtedness
Humana reported a fourth-quarter 2025 GAAP net loss of $6.61 per share, compared with a loss of $5.76 per share a year earlier, and full-year 2025 GAAP EPS of $9.84 versus $9.98 in 2024. The company introduced 2026 guidance of at least $8.89 GAAP EPS and at least $9.00 on an Adjusted basis, which it says reflects a year-over-year decline tied to the Star Ratings headwind for Bonus Year 2026, net of mitigation.
4Q25 GAAP net loss per share was $6.61; Adjusted net loss per share was $3.96
FY 2025 GAAP EPS was $9.84 (FY 2024: $9.98); FY 2025 Adjusted EPS was $17.14 (FY 2024: $16.21)
FY 2026 guidance: GAAP EPS of at least $8.89 and Adjusted EPS of at least $9.00, versus FY 2025 Adjusted EPS of $17.14
Company anticipates FY 2026 individual Medicare Advantage membership growth of approximately 25 percent over 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Humana filing is on SEC EDGAR ↗. 8-K briefs of other companies →